Nigerian Public Alert 87: The National Agency for Food and Drug Administration and Control (NAFDAC) wishes to inform healthcare professionals, distributors, wholesalers, retailers, Patent and Proprietary Medicine Vendors (PPMVs), healthcare institutions, and the general public that products marketed by Mofus Nigeria Ltd have been placed on the NAFDAC Watchlist pending the outcome of an ongoing regulatory investigation.
The decision to watch-list products associated with Mofus Nigeria Ltd, Ayrtons Saunders Ltd, UK, and Pharmaserve (North West) Ltd follows findings of significant regulatory non-compliance and potential misrepresentation, necessitating a comprehensive investigation. The case is registered under reference number NAFDAC/PMS/2026/0029 and is currently under active investigation by the Agency.
As part of the regulatory response, NAFDAC has commenced a formal investigation, activated continuous surveillance activities, issued stakeholder notifications, and encouraged the reporting of any quality concerns or irregularities associated with the affected products; see attached list.
Details of the Entity Under Investigation
| Particulars | Details |
| Case Reference Number | NAFDAC/PMS/2026/0029 |
| Product/Entity Name | Ayrtons Saunders Ltd |
| Manufacturer | PHARMASERVE (North West) Ltd |
| Country of Origin | United Kingdom |
| Marketing Authorisation Holder (MAH) | Mofus Nigeria Ltd |
| Registration Status | Registered |
| Risk Level | High |
| Current Status | Ongoing Investigation |
NAFDAC remains committed to protecting public health through continuous post-marketing surveillance, timely regulatory interventions, and enforcement actions against products and entities that may pose risks to the health and safety of the Nigerian public.
Advice to Healthcare Professionals, Distributors and the Public
NAFDAC advises all stakeholders to:
- Exercise vigilance when procuring, distributing, dispensing, or using products marketed by Mofus Nigeria Ltd.
- Purchase medical products only from licensed and authorized suppliers.
- Maintain complete distribution records to facilitate traceability where necessary.
- Immediately report any suspected quality defects, adverse events, product authentication concerns, or regulatory irregularities to the nearest NAFDAC office.
Healthcare facilities, distributors, pharmacists, and medicine vendors are advised to cooperate fully with any regulatory activities related to this investigation.
Reporting of Adverse Events and Quality Concerns
Healthcare professionals and consumers are advised to report any suspicion of the sale of substandard and falsified medicines or medical devices to the nearest NAFDAC office, call NAFDAC on 0800-162-3322, or via email: sf.alert@nafdac.gov.ng, or via the Med Safety application available for download on Android and IOS stores.
Similarly, healthcare professionals and patients are also encouraged to report adverse events or side effects related to the use of medicinal products or devices to the nearest NAFDAC office, or through the use of the E-reporting platforms available on the NAFDAC website www.nafdac.gov.ng, or via the Med- safety application available for download on Android and IOS stores, or via e-mail on pharmacovigilance@nafdac.gov.ng
PositiveNaija Nigerian Public Alert
The Nigerian Public Alert 87 initiative by PositiveNaija is aimed at keeping Nigerians well-informed particularly in regards to their safety and development. For future developments on this news, kindly follow up through the official communication channels of the reporting/regulatory authority.
We publish these alerts for free and will appreciate your support for our work – Moniepoint – 9064503292 – United Green Stars Worldwide Limited (kindly describe as “donation or gift”). Thank you.
